Spend more time living, less time worrying.

Alex Therapeutics is dedicated to supporting people living with complex conditions such as rare diseases and cancer, offering both practical and emotional support through clinically validated digital tools. These tools address unique challenges related to disease and treatment management to enable individuals to live more confidently and thrive.

Founded in 2018 by John Drakenberg, a psychologist, and Oliver Fleetwood, a theoretical computational molecular biophysicist, Alex Therapeutics combines psychology and technology to personalize healthcare. The company integrates cognitive behavioral therapy (CBT) and gamification to create engaging, user-friendly digital health products aimed at improving patient behavior and quality of life.

The company has developed regulated digital health products and is a pioneer in leveraging artificial intelligence and machine learning to enhance user experience. Alex Therapeutics collaborates mainly with pharmaceutical companies, specializing in oncology and rare diseases with complex treatment regimes and emotional distress.

The team consists of over 20 experts across psychology, engineering, design, regulatory, and market access in both the EU and US, committed to delivering high-quality personalized care globally.